Rhumbline Advisers Adicet Bio, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.21 - $2.4 $48,009 - $95,224	-39,677 Reduced 65.59%	20,819 $25,000
Q1 2024 May 09, 2024	BUY	$1.76 - $3.45 $23,550 - $46,164	13,381 Added 28.4%	60,496 $142,000
Q4 2023 Feb 08, 2024	BUY	$1.11 - $1.89 $729 - $1,241	657 Added 1.41%	47,115 $89,000
Q3 2023 Nov 09, 2023	SELL	$1.37 - $3.4 $771 - $1,914	-563 Reduced 1.2%	46,458 $63,000
Q2 2023 Aug 08, 2023	SELL	$2.13 - $7.13 $1,271 - $4,256	-597 Reduced 1.25%	47,021 $114,000
Q1 2023 May 11, 2023	BUY	$5.52 - $9.23 $12,381 - $20,702	2,243 Added 4.94%	47,618 $274,000
Q4 2022 Feb 14, 2023	BUY	$7.72 - $21.27 $20,118 - $55,429	2,606 Added 6.09%	45,375 $406,000
Q3 2022 Nov 10, 2022	BUY	$13.43 - $18.74 $37,174 - $51,872	2,768 Added 6.92%	42,769 $608,000
Q2 2022 Aug 11, 2022	BUY	$10.26 - $20.81 $85,383 - $173,180	8,322 Added 26.27%	40,001 $584,000
Q1 2022 May 12, 2022	BUY	$11.53 - $19.97 $105,614 - $182,925	9,160 Added 40.68%	31,679 $633,000
Q4 2021 Feb 10, 2022	BUY	$7.37 - $17.49 $12,551 - $29,785	1,703 Added 8.18%	22,519 $394,000
Q3 2021 Nov 12, 2021	BUY	$6.29 - $9.93 $3,541 - $5,590	563 Added 2.78%	20,816 $163,000
Q2 2021 Aug 05, 2021	BUY	$9.19 - $15.93 $186,125 - $322,630	20,253 New	20,253 $208,000

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $38.8M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.